{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T19:54:26Z","timestamp":1785614066156,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2025-MSLH-710"],"award-info":[{"award-number":["2025-MSLH-710"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1104003"],"award-info":[{"award-number":["2022YFA1104003"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330083"],"award-info":[{"award-number":["82330083"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12527-x","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:22:01Z","timestamp":1785565321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutant p53-R280K hijacks SREBP1 to promote fatty acid synthesis and breast cancer progression via FASN"],"prefix":"10.1007","volume":"53","author":[{"given":"Yihui","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menggentuya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9896-4404","authenticated-orcid":false,"given":"Qinong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"12527_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1158\/0008-5472.Can-23-2266","volume":"84","author":"T Yamamoto","year":"2024","unstructured":"Yamamoto T, Hayashida T, Masugi Y et al (2024) PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer. Cancer Res 84:1065\u20131083. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-2266","journal-title":"Cancer Res"},{"key":"12527_CR2","doi-asserted-by":"publisher","unstructured":"R\u00f6hrig F, Schulze A The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 16(2016):732\u2013749, https:\/\/doi.org\/10.1038\/nrc.2016.89","DOI":"10.1038\/nrc.2016.89"},{"key":"12527_CR3","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s42255-024-01143-3","volume":"6","author":"ED Korobkina","year":"2024","unstructured":"Korobkina ED, Calejman CM, Haley JA et al (2024) Brown fat ATP-citrate lyase links carbohydrate availability to thermogenesis and guards against metabolic stress. Nat Metab 6:2187\u20132202. https:\/\/doi.org\/10.1038\/s42255-024-01143-3","journal-title":"Nat Metab"},{"key":"12527_CR4","doi-asserted-by":"publisher","first-page":"112488","DOI":"10.1016\/j.celrep.2023.112488","volume":"42","author":"A Guilherme","year":"2023","unstructured":"Guilherme A, Rowland LA, Wetoska N et al (2023) Acetyl-CoA carboxylase 1 is a suppressor of the adipocyte thermogenic program. Cell Rep 42:112488. https:\/\/doi.org\/10.1016\/j.celrep.2023.112488","journal-title":"Cell Rep"},{"key":"12527_CR5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","volume":"34","author":"MR Morrow","year":"2022","unstructured":"Morrow MR, Batchuluun B, Wu J et al (2022) Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. Cell Metab 34:919\u2013936e918. https:\/\/doi.org\/10.1016\/j.cmet.2022.05.004","journal-title":"Cell Metab"},{"key":"12527_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763\u2013777. https:\/\/doi.org\/10.1038\/nrc2222","journal-title":"Nat Rev Cancer"},{"key":"12527_CR7","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1038\/s41388-020-1156-0","volume":"39","author":"L Gu","year":"2020","unstructured":"Gu L, Zhu Y, Lin X et al (2020) Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis. Oncogene 39:2437\u20132449. https:\/\/doi.org\/10.1038\/s41388-020-1156-0","journal-title":"Oncogene"},{"key":"12527_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12885-015-1452-1","volume":"15","author":"A Belkaid","year":"2015","unstructured":"Belkaid A, Duguay SR, Ouellette RJ, Surette ME (2015) 17\u03b2-estradiol induces stearoyl-CoA desaturase-1 expression in estrogen receptor-positive breast cancer cells. BMC Cancer 15:440. https:\/\/doi.org\/10.1186\/s12885-015-1452-1","journal-title":"BMC Cancer"},{"key":"12527_CR9","doi-asserted-by":"publisher","first-page":"156367","DOI":"10.1016\/j.phymed.2025.156367","volume":"137","author":"R Wu","year":"2025","unstructured":"Wu R, Li N, Huang W et al (2025) Melittin suppresses ovarian cancer growth by regulating SREBP1-mediated lipid metabolism. Phytomedicine 137:156367. https:\/\/doi.org\/10.1016\/j.phymed.2025.156367","journal-title":"Phytomedicine"},{"key":"12527_CR10","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhang Y, Wang Z et al The interplay of transcriptional coregulator NUPR1 with SREBP1 promotes hepatocellular carcinoma progression via upregulation of lipogenesis. Cell Death Discov 8(2022):431, https:\/\/doi.org\/10.1038\/s41420-022-01213-z","DOI":"10.1038\/s41420-022-01213-z"},{"key":"12527_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pharmthera.2017.02.021","volume":"177","author":"D Buckley","year":"2017","unstructured":"Buckley D, Duke G, Heuer TS et al (2017) Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target. Pharmacol Ther 177:23\u201331. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.021","journal-title":"Pharmacol Ther"},{"key":"12527_CR12","doi-asserted-by":"publisher","first-page":"104910","DOI":"10.1016\/j.critrevonc.2025.104910","volume":"214","author":"PV Nuzzo","year":"2025","unstructured":"Nuzzo PV, Rodrigues S, Ribeiro CF et al (2025) Targeting cancer metabolism: Therapeutic potential of the fatty acid synthase (FASN) inhibitors. Crit Rev Oncol Hematol 214:104910. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104910","journal-title":"Crit Rev Oncol Hematol"},{"key":"12527_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2021.07.029","volume":"519","author":"H Li","year":"2021","unstructured":"Li H, Chen Z, Zhang Y et al (2021) MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis. Cancer Lett 519:161\u2013171. https:\/\/doi.org\/10.1016\/j.canlet.2021.07.029","journal-title":"Cancer Lett"},{"key":"12527_CR14","doi-asserted-by":"publisher","unstructured":"Olovnikov IA, Kravchenko JE, Chumakov PM Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin Cancer Biol 19(2009):32\u201341, https:\/\/doi.org\/10.1016\/j.semcancer.2008.11.005","DOI":"10.1016\/j.semcancer.2008.11.005"},{"key":"12527_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijbiomac.2021.09.188","volume":"192","author":"LL Chen","year":"2021","unstructured":"Chen LL, Wang WJ (2021) p53 regulates lipid metabolism in cancer. Int J Biol Macromol 192:45\u201354. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.09.188","journal-title":"Int J Biol Macromol"},{"key":"12527_CR16","doi-asserted-by":"publisher","unstructured":"Vig S, Talwar P, Kaur K et al Transcriptome profiling identifies p53 as a key player during calreticulin deficiency: Implications in lipid accumulation. Cell Cycle 14(2015):2274\u20132284, https:\/\/doi.org\/10.1080\/15384101.2015.1046654","DOI":"10.1080\/15384101.2015.1046654"},{"key":"12527_CR17","doi-asserted-by":"publisher","unstructured":"Han Z, Liu M, Xie Y et al Derepression of the USP22-FASN axis by p53 loss under oxidative stress drives lipogenesis and tumorigenesis. Cell Death Discov 8(2022):445, https:\/\/doi.org\/10.1038\/s41420-022-01241-9","DOI":"10.1038\/s41420-022-01241-9"},{"key":"12527_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2013.12.025","volume":"356","author":"J Liu","year":"2015","unstructured":"Liu J, Zhang C, Hu W, Feng Z (2015) Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett 356:197\u2013203. https:\/\/doi.org\/10.1016\/j.canlet.2013.12.025","journal-title":"Cancer Lett"},{"key":"12527_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PA Muller","year":"2013","unstructured":"Muller PA, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15:2\u20138. https:\/\/doi.org\/10.1038\/ncb2641","journal-title":"Nat Cell Biol"},{"key":"12527_CR20","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.0910258107","volume":"107","author":"JW Clendening","year":"2010","unstructured":"Clendening JW, Pandyra A, Boutros PC et al (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A 107:15051\u201315056. https:\/\/doi.org\/10.1073\/pnas.0910258107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12527_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","volume":"148","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor WA, Mizuno H, Zhao X et al (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244\u2013258. https:\/\/doi.org\/10.1016\/j.cell.2011.12.017","journal-title":"Cell"},{"key":"12527_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2006.10.009","volume":"250","author":"M Koyuturk","year":"2007","unstructured":"Koyuturk M, Ersoz M, Altiok N (2007) Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 250:220\u2013228. https:\/\/doi.org\/10.1016\/j.canlet.2006.10.009","journal-title":"Cancer Lett"},{"key":"12527_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/1471-2164-9-486","volume":"9","author":"L Vrba","year":"2008","unstructured":"Vrba L, Junk DJ, Novak P, Futscher BW (2008) p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics 9:486. https:\/\/doi.org\/10.1186\/1471-2164-9-486","journal-title":"BMC Genomics"},{"key":"12527_CR24","doi-asserted-by":"publisher","first-page":"166868","DOI":"10.1016\/j.bbadis.2023.166868","volume":"1870","author":"YJ Kwon","year":"2024","unstructured":"Kwon YJ, Kwon TU, Shin S et al (2024) Enhancing the invasive traits of breast cancers by CYP1B1 via regulation of p53 to promote uPAR expression. Biochim Biophys Acta Mol Basis Dis 1870:166868. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166868","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"12527_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4196\/kjpp.2013.17.4.291","volume":"17","author":"YH Bae","year":"2013","unstructured":"Bae YH, Ryu JH, Park HJ et al (2013) Mutant p53-Notch1 Signaling Axis Is Involved in Curcumin-Induced Apoptosis of Breast Cancer Cells. Korean J Physiol Pharmacol 17:291\u2013297. https:\/\/doi.org\/10.4196\/kjpp.2013.17.4.291","journal-title":"Korean J Physiol Pharmacol"},{"key":"12527_CR26","doi-asserted-by":"publisher","unstructured":"Bellazzo A, Sicari D, Valentino E, Del Sal G, Collavin L Complexes formed by mutant p53 and their roles in breast cancer. Breast Cancer (Dove Med Press) 10(2018):101\u2013112, https:\/\/doi.org\/10.2147\/bctt.S145826","DOI":"10.2147\/bctt.S145826"},{"key":"12527_CR27","doi-asserted-by":"publisher","unstructured":"Pfister NT, Fomin V, Regunath K et al Mutant p53 cooperates with the SWI\/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev 29(2015):1298\u20131315, https:\/\/doi.org\/10.1101\/gad.263202.115","DOI":"10.1101\/gad.263202.115"},{"key":"12527_CR28","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1128\/mcb.25.17.7423-7431.2005","volume":"25","author":"JS Ho","year":"2005","unstructured":"Ho JS, Ma W, Mao DY, Benchimol S (2005) p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 25:7423\u20137431. https:\/\/doi.org\/10.1128\/mcb.25.17.7423-7431.2005","journal-title":"Mol Cell Biol"},{"key":"12527_CR29","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1038\/ncomms3935","volume":"4","author":"C Zhang","year":"2013","unstructured":"Zhang C, Liu J, Liang Y et al (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 4:2935. https:\/\/doi.org\/10.1038\/ncomms3935","journal-title":"Nat Commun"},{"key":"12527_CR30","doi-asserted-by":"publisher","unstructured":"Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature 531(2016):110\u2013113, https:\/\/doi.org\/10.1038\/nature16967","DOI":"10.1038\/nature16967"},{"key":"12527_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y (2023) Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther 8:92. https:\/\/doi.org\/10.1038\/s41392-023-01347-1","journal-title":"Signal Transduct Target Ther"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12527-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T19:02:32Z","timestamp":1785610952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12527-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12527"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12527-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were approved by the Institutional Animal Care Committee of Academy of Military Medical Sciences (Approval Code: IACUC-DWZX-2022-514; Approval Date: 21 January 2022; Beijing, China) and were performed in accordance with the revised Animals (Scientific Procedures) Act 1986. The animal experiments also complied with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines (\n                      \n                      ).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1320"}}